A new study published in the Journal of American Medical Association showed that dupilumab (Dupixent), used for treating ...

Shares of Nektar Therapeutics soared after the company said it would release topline data from a study of its atopic dermatitis treatment rezpegaldesleukin. The stock was up 31% at $12.49 in Monday's ...

Investing.com -- Nektar Therapeutics (NASDAQ: NKTR) stock surged 20% following the company’s announcement that it will present top-line data from its REZOLVE-AD Phase 2b clinical trial for atopic ...

Nektar Therapeutics said it would release topline data from a study of its atopic dermatitis treatment rezpegaldesleukin on Tuesday. Shares climbed 27% to $12.15 in after-hours trading Monday.

Incyte INCY announced that the FDA has extended the review period for the supplemental new drug application (sNDA) for ...

This study reveals that dupilumab is associated with a modestly increased risk of developing psoriasis, highlighting the ...

Compared with other systemic agents for treating atopic dermatitis, dupilumab is associated with an increased risk for ...

Zai Lab Limited (NASDAQ:ZLAB) is one of the 10 biotech stocks screaming a buy. On June 17, the company delivered positive ...

Having secured one of last year’s largest funding rounds, AI-focused Formation Bio is now eyeing up 545 million euros ($626 ...

Discover a study that found that children with early AD were more likely to develop food allergies, whereas those with later ...

Key findings of subgroup analyses included an observed increased psoriasis risk in patients without atopic comorbidities (HR 1.42, 95% CI 1.06-1.89) and those with pretreatment immunoglobulin E (IgE) ...